Dynamic Biosystems Completes Nearly RMB 100 Million Series A+ Financing to Lead Clinical Translation of Single-Cell Spatial Omics

Recently, Suzhou Dynamic Biosystems Co., Ltd. (hereinafter referred to as “Dynamic Biosystems”) announced the completion of its Series A+ financing round, raising nearly RMB 100 million. The round was led by Longpan Investment, with Ruihua Capital participating as a co-investor, and existing shareholder Guanya Investment continuing to increase its stake. The funds raised will be used to strengthen the company’s strategic layout and maintain its leading advantage in the clinical application of single-cell spatial omics. As a pioneer in China’s single-cell spatial omics sector, Dynamic Biosystems has taken the lead in introducing a novel RNA in situ sequencing technology for spatial omics with subcellular resolution. It has rapidly commercialized the single-molecule RNA in situ hybridization component of this technology, obtained medical device registration, and facilitated the translation and implementation of multiple clinical-grade spatial omics products.

Dynamic Biosystems possesses leading foundational technologies and original capabilities at the global forefront of single-cell spatial omics. The company’s founder, chairman, and chief scientist, Professor Yang Chaoyong, is an internationally renowned expert in microfluidics and single-cell analysis. He has undertaken multiple national-level key projects, major research initiatives, and special programs for the development of major national scientific instruments, and has been granted over 40 invention patents related to single-cell identification, enrichment, and sequencing. Dr. Ke Rongqin, the company’s deputy general manager and chief scientist of in situ technology, was the first author of the inaugural paper on in situ sequencing published in Nature Methods and is one of the global inventors of in situ sequencing technology. Formerly a senior scientist at Complete Genomics, he brings profound expertise in the foundational technologies underlying sequencing.

Professor Yang Chaoyong, Founder, Chairman, and Chief Scientist of Dynamic Biosystemsstated, “The company continues to strengthen its innovative capabilities in the field of single-cell spatial omics. Following the successive launches of its single-cell omics technologies, Digital-seq and Well-paired-seq, it has pioneered a novel RNA in situ sequencing technology in the spatial omics domain. We are proud to have the opportunity to conduct unprecedented clinical translation explorations in the vast frontier of single-cell spatial omics, contributing Chinese wisdom to human health.”

Li Jiacheng, Managing Director/CEO of Dynamic Biosystemsstated: “From the outset, the company has been committed to advancing precision medicine into the era of single-cell and spatial omics, with a strong focus on harnessing the clinical application potential of these revolutionary technologies. We have established strategic collaborations with leading in vitro diagnostics (IVD) companies, leveraging our Digital-seq single-cell omics technology to pioneer clinical applications. Furthermore, through partnerships with top-tier tertiary hospitals, we have accelerated the clinical translation of spatial omics technologies, earning significant recognition and high expectations from clinical customers. This round of investment will undoubtedly strengthen the company’s industry-leading position in the clinical translation of single-cell and spatial omics technologies.”

Mr. Yu Zhihua, Founding Partner of Longpan Investment“Dynamic Biosystems is a biotechnology company with in-depth deployment across the entire chain of single-cell sequencing and spatial multi-omics platforms. Its in situ sequencing products are at the global forefront in terms of R&D progress, product performance, and clinical translation. We look forward to Dynamic Biosystems rapidly bringing products with clinical application potential to market, thereby benefiting patients worldwide.”

Ms. Lu Xinghua, Ruihua Capitalstated: “As a pivotal spatial omics technology, in situ sequencing can directly visualize gene expression at subcellular resolution within the native tissue context, representing a cutting-edge approach that seamlessly integrates histopathology with molecular pathology. It holds significant promise for advancing precise pathological diagnosis of tissue-derived specimens, diagnostics related to tumor immunotherapy, and analysis of the tumor microenvironment. Following comprehensive research and comparison, we highly recognize Dynamic Biosystems’ leading position in the clinical translation of single-cell spatial omics.”

Mr. Gu Yuming, Vice President of Guanya Investmentstated: “Dynamic Biosystems is an outstanding innovative enterprise specializing in single-cell spatial omics technology. The company focuses on the application market for single-cell spatial omics and has introduced a professional team for industrialization and operations. Its spatial omics product pipeline demonstrates significant clinical innovation. We participated in its Pre-A round of financing and hope to continue our support in this round, expecting the company to consistently launch products with global impact that benefit human health.”

Dynamic Biosystems (www.dynamic-biosystems.com) is a technology platform enterprise specializing in single-cell and spatial multi-omics. The company focuses on unlocking the immense potential of these technologies in precision oncology, eugenics and healthy reproduction, and drug discovery. Committed to advancing precision medicine into the era of single-cell and spatial omics, Dynamic Biosystems supports life sciences and clinical medicine, contributing Chinese expertise to the global cause of human health. The company has established R&D laboratories, Class 100,000 cleanroom facilities, and business offices totaling over 6,000 square meters in Suzhou and Xiamen, and has obtained multiple certifications, including the GB/T 19001-2016/ISO 9001:2015 Quality Management System. Currently employing nearly 150 staff members, with over 30% holding master’s degrees or higher (including more than 10 PhDs), the company provides users with a one-stop, end-to-end comprehensive solution for single-cell and spatial omics, covering sample dissociation, cell capture, library construction, sequencing analysis, data mining, and personalized analysis. Dynamic Biosystems has launched the Digital-seq trace single-cell omics platform and the Well-paired-seq high-throughput single-cell sequencing platform. It was also the first in China to introduce a flagship spatial omics product with subcellular resolution—the novel RNA in situ sequencing technology. To date, the company has established business collaborations with more than 40 renowned universities and hospitals. Dedicated to bridging the gap from research to clinical application, Dynamic Biosystems is a leader in the clinical translation of single-cell spatial omics. Multiple spatial omics products based on single-molecule RNA in situ hybridization and in situ sequencing are currently undergoing clinical registration or are in development, covering diagnostic applications in therapeutic areas such as cervical cancer, liver cancer, breast cancer, lung cancer, and colorectal cancer.

The company was selected for the 2020 Wujiang Leading Sci-Tech Talent Program (Key Category) and the 2021 Gusu Leading Talent Project. It won first place in the biopharmaceutical sector of the Startup Group at the Finals of the 9th “Entrepreneurship Jiangsu” Sci-Tech Entrepreneurship Competition in 2022, received the First Prize for Xiamen Science and Technology Progress in 2021, was recognized as a Jiangsu Province Quality Credit Grade A Enterprise, and was named one of the Top Ten Innovative Enterprises in the Wujiang Development Zone in 2022. Additionally, it was included in 36Kr’s list of “Medical Enterprises with 10x Growth Potential” and on Suzhou City’s list of “Unicorn” Cultivation Enterprises.

LongPan Investment, headquartered in Beijing, is a leading biomedical venture capital firm in China. The firm currently manages five RMB-denominated funds and one USD-denominated fund, with total assets under management exceeding RMB 10 billion. LongPan Investment focuses on innovative drugs and innovative medical devices, primarily investing at the startup and early-to-mid stages. To date, it has invested in more than 80 companies in these sectors, including notable portfolio companies such as Betta Pharmaceuticals (SZ.300558), RemeGen (SH.688331), Aier Eye Hospital Group’s subsidiary Aibo Medical (SH.688050), Clover Biopharmaceuticals (HK.02197), Yihua Pharmaceutical (SH.688176), Huamai Technology, Swire Microbes, and BinHui Biotech. Many partners in LongPan Investment’s management team bring over 20 years of R&D and managerial experience in the global and domestic biomedical industries, enabling the firm to provide comprehensive value-added services to its portfolio companies.

Ruihua Capital’s business scope encompasses investments in the secondary equity market, private equity, private placements, private (trust) funds, and financial derivatives. Its equity investment strategy focuses on key sectors such as big health, new energy, and semiconductors. Upholding the Ruihua values of “Integrity, Excellence, Win-Win Cooperation, Long-Term Vision, and Ethical Practice,” the firm provides comprehensive value-added services to enterprises, serving as their long-term strategic partner.

Founded in 2004, Guanya Investment is one of the earliest private equity investment firms established in China. It initiated the establishment of China’s second partnership-based equity investment fund. Headquartered in Shanghai, the firm has set up branches in Suzhou, Shenzhen, and Xiamen. The company focuses on investments in advanced manufacturing, healthcare, and semiconductors. It has initiated, established, and managed nearly 30 funds, including advanced manufacturing industry funds, government guidance funds, Pre-IPO funds, venture capital (VC) funds, and specialized semiconductor and healthcare funds. Committed to investing in “Specialized, Refined, Differential, and Innovative” (SRDI) growth enterprises, Guanya Investment consistently practices empowerment and value sharing, continuously creating value for investors and portfolio companies, and has helped more than 30 companies successfully enter the capital markets. In 2020, the number of its portfolio companies that went public ranked joint 19th among PE/VC firms nationwide according to China Venture (CVSource). In 2021, its investment in GoodWe was honored as one of the “Top 10 Investment Cases in China’s Advanced Manufacturing” by Zero2IPO Group. In 2022, it ranked 18th among private equity investment firms on the “LP Think Tank SRDI List.”